What’s in Store for HIV Prevention in the Future?

Once upon a time, our HIV prevention toolkit consisted of just one lousy, dull instrument: condoms.

Nowadays, we have not only condoms in all colors, shapes and sizes, but also female condoms (hint: you don’t have to be female to use them), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) and the mama of all discoveries: HIV treatment as prevention (TasP). And exciting research keeps chugging along, seeking provide even more, safer, sexier, accessible ways for people living with and without HIV to get down without concern about HIV transmission.

Here are a few of the tools currently in the study “pipeline” that will shape the future of HIV prevention.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below